Frontiers in Medicinal Chemistry

Volume 7

by

Atta-ur-Rahman , M. Iqbal Choudhary , Jizhou Wang, Allen B. Reitz

DOI: 10.2174/97816080597061150701
eISBN: 978-1-60805-970-6, 2015
ISBN: 978-1-60805-971-3
ISSN: 1567-2042 (Print)
ISSN: 1875-5763 (Online)



Indexed in: Book Citation Index, Science (BKCI-S), Web of Science, BIOSIS Previews, EMBASE, Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

“Frontiers in Medicinal Chemistry” is an Ebook series devoted to the review of ...[view complete introduction]
US $
Buy Personal eBook
190
Order Library eBook
760
Order Printed Copy
*190
Order PDF + Printed Copy (Special Offer)
*285

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Also available:
Download Flyer

Dopamine Receptor Agonists for Protection and Repair in Parkinson's Disease: An Update

- Pp. 87-106 (20)

Giulia Ferrari-Toninelli, Sara A. Bonini, Paola Bettinsoli, Giuseppina Maccarinelli, Giovanna Cenini, Mariagrazia Grilli, Daniela Uberti and Maurizio Memo

Abstract

Dopamine agonists have been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinson’s disease models, because their capability to counteract- neuronal cell death. Here we update the molecular evidence underlying the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinson’s disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These activities are moleculespecific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role. However, despite increasing number of experimental results confirm their neuroprotective effects, further studies are needed to definitively confirm dopamine agonists as disease-modifying agents.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science